Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan

References

• Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751–767.
   PubMed Web of Science ®Google Scholar
• Hiroi S, Sugano K, Tanaka S, et al. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open. 2017;7:e015855.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter 2017;22:e12415–e12405.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Nishiyama Y, Yamaoka M, et al. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years. J Gastroenterol Hepatol. 2010;25:S99–S110.
   PubMed Web of Science ®Google Scholar
• Tytgat GN. Are there unmet needs in acid suppression? Best Pract Res Clin Gastroenterol. 2004;(18 Suppl):67–72.
   PubMed Web of Science ®Google Scholar
• Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease? Clin Trans Gastroenterol. 2015;6:e119.
   PubMed Web of Science ®Google Scholar
• Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048–1059.
   PubMed Web of Science ®Google Scholar
• Shinozaki S, Osawa H, Hayashi Y, et al. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. Kaohsiung J Med Sci. 2017;33:616–622.
   PubMed Web of Science ®Google Scholar
• Shinozaki S, Osawa H, Hayashi Y, et al. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2017;7:231–235.
   PubMed Web of Science ®Google Scholar
• Kakuta E, Yamashita N, Katsube T, et al. Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Intern Med. 2011;50:1517–1522.
   PubMed Web of Science ®Google Scholar
• Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–180.
   PubMed Web of Science ®Google Scholar
• Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.
   Google Scholar
• Yoshioka T, Okimoto N, Okamoto K, et al. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients. J Bone Miner Metab. 2013;31:153–160.
   PubMed Web of Science ®Google Scholar
• Fujishiro M, Kushiyama A, Yamazaki H, et al. Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus. World J Gastroenterol. 2017;23:6694–6704.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Chiba T. Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: based on the large-scale survey, FUTURE study. Intern Med. 2011;50:2269–2276.
   PubMed Web of Science ®Google Scholar
• Okimoto E, Ishimura N, Morito Y, et al. Prevalence of gastroesophageal reflux disease in children, adults, and elderly in the same community. J Gastroenterol Hepatol. 2015;30:1140–1146.
   PubMed Web of Science ®Google Scholar
• Shinozaki S, Osawa H, Sakamoto H, et al. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63:230–235.
   PubMed Web of Science ®Google Scholar
• Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003;98:S31–S39.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Trans Gastroenterol. 2015;6:e94.
   PubMed Web of Science ®Google Scholar
• Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther. 2004;19:1105–1115.
   PubMed Web of Science ®Google Scholar
• Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466–1479.
   PubMed Web of Science ®Google Scholar
• Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther. 2004;19 Suppl 1:28–34.
   PubMed Web of Science ®Google Scholar
• Miwa H, Nakajima K, Yamaguchi K, et al. Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther. 2007;26:257–264.
   PubMed Web of Science ®Google Scholar
• Iwakiri R, Tominaga K, Furuta K, et al. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther. 2013;38:729–740.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(4):CD001960.
   PubMed Web of Science ®Google Scholar
• Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–695.
   PubMed Web of Science ®Google Scholar
• Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24:1550–1561.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–715.
   PubMed Web of Science ®Google Scholar
• Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;(12):CD010623.
   PubMed Web of Science ®Google Scholar
• Sato Y, Imamura H, Kaizaki Y, et al. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan. Dig Endosc. 2014;26:377–384.
   PubMed Web of Science ®Google Scholar